ArticlePharmaceutical research2009
Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics · 2022Review
- Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario.Current pharmaceutical design · 2022Review
- Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Dry Powder for Pulmonary Delivery: A Comprehensive Review.Pharmaceutics · 2020Review
- Novel Approaches for the Treatment of Pulmonary Tuberculosis.Pharmaceutics · 2020Review
- Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung cancer management · 2020Review
- Inhaled Cisplatin for NSCLC: Facts and Results.International journal of molecular sciences · 2019Review
- Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.International journal of nanomedicine · 2019Article
- Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.Acta pharmacologica Sinica · 2017Review
- Advances in device and formulation technologies for pulmonary drug delivery.AAPS PharmSciTech · 2014Review
- Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.British journal of cancer · 2013Article
- New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.International journal of nanomedicine · 2012Article
- Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.International journal of molecular sciences · 2012Review
- Inhaled chemotherapy in lung cancer: future concept of nanomedicine.International journal of nanomedicine · 2012Review
- Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2011Article
- Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.Pharmaceutical research · 2011Article
- Building membrane emulsification into pulmonary drug delivery and targeting.Pharmaceutical research · 2010Article
- Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization.Molecular pharmaceutics · 2010Article
- Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.International journal of pharmaceutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeTo develop an aerosol system for efficient local lung delivery of chemotherapeutics where nanotechnology holds tremendous potential for developing more valuable cancer therapies. Concurrently, aerosolized chemotherapy is generating interest as a means to treat certain types of lung cancer more effectively with less systemic exposure to the compound.
methodsNanoparticles of the potent anticancer drug, paclitaxel, were controllably assembled to form low density microparticles directly after preparation of the nanoparticle suspension. The amino acid, L-leucine, was used as a colloid destabilizer to drive the assembly of paclitaxel nanoparticles. A combination chemotherapy aerosol was formed by assembling the paclitaxel nanoparticles in the presence of cisplatin in solution.
resultsFreeze-dried powders of the combination chemotherapy possessed desirable aerodynamic properties for inhalation. In addition, the dissolution rates of dried nanoparticle agglomerate formulations (approximately 60% to 66% after 8 h) were significantly faster than that of micronized paclitaxel powder as received (approximately 18% after 8 h). Interestingly, the presence of the water soluble cisplatin accelerated the dissolution of paclitaxel.
conclusionsNanoparticle agglomerates of paclitaxel alone or in combination with cisplatin may serve as effective chemotherapeutic dry powder aerosols to enable regional treatment of certain lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.